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ABSTRACT
BACKGROUND: Vitiligo is a chronic skin condition among psychocutaneous diseases that
significantly affect psychiatric well-being of patients, social interactions, and overall quality of
life. Only a limited number of studies about psychiatric well-being and quality of life in
children with vitiligo and their parents are available.
AIMS: With this study, we aimed to assess anxiety, depression, and quality of life in children
diagnosed with vitiligo and their parents.
METHODS AND MATERIAL: Forty-one vitiligo patients aged 9–16 years 30 healthy controls
along with their parents were asked to fill out self-report forms that assessed quality of life
(Pediatric Quality of Life Inventory – Child Form; PedsQL-C and Pediatric Quality of Life
Inventory – Parent Form; PedsQL-P), anxiety (State–Trait Anxiety Inventory – STAI-C for
children and Beck Anxiety Inventory – BAI for parents), and depression (Children’s Depression
Inventory – CDI and Beck Depression Inventory – BDI for parents).
RESULTS: Between groups, significant differences were found in PedsQL-C subscales measuring
school functioning, psychosocial health, and overall quality of life. Regarding PedsQL-P scores,
there was a significant difference in physical functioning, social functioning, and overall quality
of life. No statistical significance was found between groups regarding CDI and STAI-C scores.
There was a significant difference in BDI, with higher scores in parents of children with vitiligo.
CONCLUSIONS: We believe measuring life quality with standardized instruments and
techniques would be important in the assessment of the patient to evaluate the efficacy of
treatment, specifically in chronic disorders. Further studies addressing these issues, especially
in children, adolescents, and their parents are warranted.
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Key-messages
Hopefully contributing to the existing literature, this
small-size study found that parents of children with
vitiligo have a worse perception of their children’s
overall quality of life, causing specifically a difference
in the perception of physical functioning, which
needs to be further addressed and studied with larger
samples.
Introduction
Vitiligo is an expansive and widespread skin disorder
characterized by limited hypomelanosis in skin and
hair, where total melanocyte loss is observed on a
microscopic level [1]. As classified among psychocuta-
neous diseases, vitiligo significantly affects psyche of
the patient and his/her interpersonal relationships,
not to mention the quality of life [2,3]. It is commonly
known that brain and skin develop from similar
embryological origins and skin responses to stimuli
have both physiological and psychological
consequences [4]. Worldwide prevalence of vitiligo
has been reported as 0.06–2.28% [5], and 50% of the
cases are reported to be younger than 20 years old
[6,7]. In a study conducted in Turkey, it was reported
that 0.15–0.32% of patients that apply to dermatology
outpatient units were diagnosed with vitiligo [8]. Viti-
ligo – as a psychosomatic phenomenon that emerges
due to physical and psychological factors where clinical
manifestations might include progressive, relapsing,
and remitting forms – is largely believed to create a
severe burden on the lives of both patients and their
families.
It is a well-known fact that stress either induces
emergence of various dermatological diseases or
causes an increase in severity of skin symptoms
[9,10]. Physiological factors that cause emotional
stress might be triggers in the formation or exacer-
bation of various dermatological diseases [10–12]. In
more than one-third of individuals with a dermatolo-
gical problem, efficient treatment of skin lesions has
been linked to effective management of related
psychological stressors [13]. Skin disorders might
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pose negative social outcome as body image is very
important, specifically within certain ages [14,15].
Vitiligo might bear an adverse clinical presentation
both in short- and long-term over the life of the
patients [7,16]. Vitiligo affects the individual’s life
rather negatively and might turn out to be destructive
and cause stigmatization [17–21]. For most of the
cases, vitiligo is a progressive disorder that cannot be
foreseen regarding its clinical characteristics [22]. In
cases with vitiligo, it has been defined that quality of
life might be connected to various factors and onset
at younger ages is related to worse overall levels of
life quality [23,24]. A limited number of studies exist
in the literature that aims to evaluate emotional bur-
den caused by vitiligo and the effect of the illness on
psychosocial development, specifically in children
and adolescents [25]. As there is one study that
reported worse quality of life among children with
vitiligo, compared to those with atopic dermatitis
[26], Bilgic et al. [27] have also reported that for pre-
pubertal children, severity of vitiligo correlated with
severity of depression, while in adolescents, lower
levels of life quality have been reported especially if
the lesions were located in body parts that were visible
to others. In cases with lesions located in visible body
regions, it has been reported that stigma related to the
disorder might pose an increased risk for developing a
psychiatric illness or a disorder, along with lower
levels of quality of life, assessed [7,14,28].
It has been long identified that children were
especially vulnerable to inorganization within the
household and this condition might cause psychoso-
matization at early ages [7,28,29]. As for caregivers,
most commonly emerging psychiatric diagnoses fol-
lowing paediatric dermatosis have been defined as
anxiety and depression [30–35]. In quality of life
studies conducted with relatives of individuals with
chronic skin conditions, anxiety and depression have
frequently been underlined [28,36–38]. This might be
related to the fact that the caregiver not possessing
good-enough adjustment mechanisms in confronting
his/her child’s illness, through a disruption in the
ideal image of their children within the parents’
minds, following an adversity emerging regarding the
physical appearance of the child [39]. According to
studies that evaluate patients’ quality of life and levels
of anxiety and depression, a significant relationship
exists between the decline in the patient’s quality of
life and both depression and anxiety levels of the
parents. Emotional vulnerability is typical among
these cases; exposure to adverse experiences is related
to anxiety and depression in caregivers and this
might, in turn, decrease the overall life quality of the
caregivers [15].
While it has been reported a negative influence on
both physical and psychosocial well-being arose in
other chronic skin disorders such as psoriasis and
atopic dermatitis, vitiligo patients have been identified
as having a much more detrimental effect on their psy-
chosocial well-being [17–21]. Sampogna et al. [6] have
reported significant correlation between quality of life
levels and depressive symptoms and alexithymia.
Unlike many other medical conditions, skin disorders
are easily noticed by other people. Even though vitiligo
does not directly cause a physical distress, it might
cause discomfort as it disrupts the physical appearance
and affects the psyche in a very negative way [6,40].
Studies in this field indicate that patients with vitiligo
might experience low self-esteem [23] and depression
[6,41]. Brown et al. [42] have defined depression,
adjustment disorder, dysthymia, and other psychiatric
disorders in 25% of vitiligo cases that had applied to
outpatient units, while Sangma et al. [43] have
described a comorbidity rate with psychiatric disorders
such as depression, in approximately 59% of cases
afflicted with the skin condition. One of the potential
mechanisms that might explain the depigmentation
observed as part of the disorder’s clinical presentation,
is believed to have links to neuroendocrine dysregula-
tion, a causal factor responsible for developing
depression. It has widely been suggested that increased
levels of norepinephrine and acetylcholine play a sig-
nificant role [44] and the onset of pigment loss in
62–65% of the cases would be triggered by psychologi-
cal stress [45]. As a response to psychic stress, through
the activation of hypothalamic–pituitary–adrenal axis,
catecholamine discharge occurs and by binding to
alpha-receptors on dermal arterioles and activation,
vasoconstruction, hypoxia, and production of excessive
free oxygen radicals are triggered, resulting in destruc-
tion of melanocytes [46,47].
Prevalence of depression among vitiligo patients has
been reported ranging between 10% and 60%, depend-
ing on the sample size of the study and characteristics
of the research population [43,48]. Approximately 1/3
of vitiligo patients were said to have reported depress-
ive symptoms or impaired general health issues, while
close to one-fourth of the given population met diag-
nostic criteria for clinical depression [49]. There are
studies in literature suggesting that depressive symp-
toms might predict overall life quality [6,50]. Studies
regarding psychosocial effects are limited [3]. Decline
in social support has been defined as a significant and
major area of problem for patients [51]. Successful
identification and effective management of psychologi-
cal compounds of the disease carry much importance
in increasing quality of life and obtaining a better treat-
ment response [2].
Although studies that assess quality of life, anxiety,
and depression in children diagnosed with vitiligo
exist in other countries, research conducted in Turkey
is still scarce and insufficient. This study aimed to
assess anxiety, depression, and quality of life in chil-
dren diagnosed with vitiligo and their parents.
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Subjects and methods
Patients aged 9-18 years old who had applied to the
Dermatology Unit of the research hospital were chosen
for this study, and trials were conducted between the
dates 01.02.2016 and 01.08.2016, which would be cov-
ering a timeframe of six months. Of these, children
who have been followed up with the diagnosis of viti-
ligo for at least three months and their parents were
included consecutively in the study sample. Patients
who are being followed up due to vitiligo had been reg-
ularly attending their visits and each patient had differ-
ent treatment periods. The medical status of the
patients was determined and recorded by the physical
examination of the attending dermatology specialist.
Then, cases were referred to the child psychiatry
department of the same hospital. Patients and their
parents (mainly their mothers and in some, their pri-
mary caregivers) were asked to fill out scales that
measured anxiety, depression, and quality of life. Psy-
chiatric assessments of cases and controls were carried
out through routine psychiatric interviewing. Children
with a history of any chronic physical disorder or
systemic drug use were excluded from the study.
Same exclusion criteria were also used for the control
group. Prior history of having received psychiatric
treatment or psychotropic drug use was not among
exclusion criteria, neither for the case group nor for
controls.
Taking into a recent and relevant study’s method-
ology [27] as well as a calculated effect size of 0.8097
with alpha values = 0.05 and power value = 0.95,
measured via G-power programme, the total number
of individuals who would be recruited in the study
was calculated as 82, who are divided into 2 groups –
41 were included in the case group and 41 in the con-
trol group. 41 children and adolescents as well as their
parents who had applied to the unit within planned
three-month data collection span of the study and
gave consent to be included in the study were recruited,
while it was possible to collect the data of 30 age- and
gender-matched children and adolescents included in
the control group. Comparisons between groups were
made, as targeted sample size was obtained for con-
ducting parametric tests. Children and adolescents in
the control group consisted of children with no history
of a chronic disease, that had applied to the Paediatric
Department of the hospital for routine check-up, where
the study was conducted.
Ethical approval was obtained from the Ethical
Board of the hospital and informed consent was
obtained from all cases and their parents upon giving
detailed information orally and through written
forms about the study.
Our single-centre study of cross-sectional case-
control design, data measured by Pediatric Quality
of Life Inventory (PedsQL), Child Depression Inven-
tory (CDI), and State–Trait Anxiety Inventory for
Children (STAI-C) applied to the case group were
compared to those obtained from the application of
same measurements to individuals constituting the
control group, matched by age and gender. Parents
(mostly mothers) were evaluated with Beck
Depression Inventory (BDI) and Beck Anxiety Inven-
tory (BAI), and were also asked to fill out PedsQL –
parent version. Therefore, it would possibly be
appropriate to identify our research as having
employed a single methodology (containing self-
report scales and one other data form) with multi-
trait features (CDI, STAI-C and PedsQL – Child
Form; BDI, BAI, and PedsQL – Parent Form).
The Vitiligo Area Severity Index (VASI) scoring sys-
tem was used to determine the severity of the disorder.
Percentage value indicating the affliction of the dis-
order was evaluated based on employing the hand
unit measurement technique. A single hand unit
would approximately be equal to 1% of the total body
surface area. The degree of pigmentation for each
body area is measured by using percentage values.
VASI has been identified as the most valid indices in
the evaluation of determining the extent and severity
of the disorder and safe to be used under any circum-
stance [52]. Through employing this scoring system,
afflicted and non-afflicted zones of all other specific
parts of the body (such as hands, feet, breasts, and gen-
ital area) could be measured. Information regarding
having experienced any stressor event prior to the
onset of illness was retrieved from both cases and
their parents, through interrogation during the psy-
chiatric interview.
Assessment tools
Child Depression Inventory
CDI is a 27-item self-report form developed by Kovacs
[53] that could be applied to children between 6 and 17
years old. Turkish validity and reliability study was car-
ried out by Öy [54] and the pathological cut-off score
was maintained as 19 points [54].
Beck Depression Inventory
BDI is a 21-item self-report form that aims to measure
physical, emotional, cognitive, and motivational symp-
toms seen in depression. Upon scoring on a scale ran-
ging from 0 to 3 for each question, the total score is
summed up and scores over 17 are defined as possibly
indicating clinical depression. The scale was initially
developed by Beck et al. in 1961 [55] and went on
being used with the updated version developed by
same researchers in 1979. Turkish adaptation and psy-
chometric study were conducted by Hisli [56].
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State–Trait Anxiety Inventory for Children
Developed by Spielberger, this scale has two subscales,
each containing 20 questions with multiple choice
answers; for state (A-State) and trait anxiety (A-
Trait), separately. Each item is scored as 1, 2, or 3
according to symptom severity, in turn, making the
minimum score 20 and maximum 60 points one
could get from the scale. State anxiety refers to the
anxiety felt by an individual at a certain time and cir-
cumstance; therefore might alter depending on exter-
nal factors. On the other hand, trait anxiety defines
how the individual feels in general and also reflecting
the proneness of that individual to anxiety. Validity
and reliability study of the scale was carried out by
Özusta in our country, indicating fine clinical utility
in children aged between 9 and16 years [57,58].
Beck Anxiety Inventory
BAI was initially developed by Beck et al. in 1961 and
adapted into Turkish by Ulusoy et al. BAI is a self-
report form to determine the frequency of anxiety the
individual experiences. The scale is Likert-type consist-
ing of 21 items and each item is scored between 0 and
3. Scores range between 0 and 63, with higher scores
reflecting much severe anxiety for that specific individ-
ual [59,60].
Pediatric Quality of Life Inventory
PedsQL is a scale that assesses life quality developed by
Varni et al. in 1999, upon thorough assessments that
lasted for nearly 15 years [61]. The scale mainly inter-
rogates core functioning domains of overall well-being
identified by World Health Organization (WHO),
including physical health, emotional, social, and aca-
demic functioning. The scale reflects a general opinion
for quality of life, that could be used in children and
adolescents aged between 2 and 18 years old. The
scale also has four different versions that contain age-
adjusted questions assessing same domains described
before, designed for children aged between 2– and 4
years, 5and 7 years, 8 and 12 years, and 13 and 18
years old. Made up of four subsections that assess phys-
ical, emotional, social, and academic functions, separ-
ate scoring for each domain (emotional functioning
score (EFS), physical functioning score (PFS), social
functioning score (SoFS), and school functioning
score (ScFS)) as well as psychosocial health summary
score (PHSS) and total scale score (TSS) could be
used during assessment. This scale interrogates the
situation of the child/adolescent within the past
month and was developed into a Likert-type question-
naire with 5 points to be used in children and adoles-
cents aged between 8 and 18 years. Items are scored
ranging from 0 to 100. Scores from each item are
summed up to be divided into the number of items,
yielding to the total score. Higher total PedsQL scores
indicate a better perception of health-related quality of
life [62]. PedsQL has both self-report forms for chil-
dren and adolescents aged between 5 and 18 years
old (PedsQL-C) and parent-proxy forms (PedsQL-P)
[61]. Turkish validity and reliability studies of self-
report and parent forms for children aged 8–12 and
13–18 years old were carried out by Memik et al.
[63,64].
Statistical analysis
In this study, Statistical Package for Social Sciences
Programme for Windows 20.0 version (SPSS, 20.0)
was used as the software programme for statistics.
For group comparisons, chi-square test was used for
categorical variables while Student t test was preferred
for continuous variables. The statistical significance
level was determined at p < .05. By using Kolmo-
gorov–Smirnov test, it was shown that parameters
were in accordance with normal distribution.
Results
No statistically significant difference was found
between children and adolescents within the vitiligo
group and healthy control group regarding gender
and age (Tables 1 and 2).
The average time that had elapsed upon being diag-
nosed with vitiligo was 22.7 ± 35.7 (3–144) months and
mean level of vitiligo severity was 3.3 ± 2.9 (1–16).
Patients with vitiligo were ranged within a wide spec-
trum, according to the severity of the disease, and
those with high levels of severity were scarce.
Between groups, significant differences were found
in mean scores of PedsQL-C form subscales that
measured ScFS, PHSS, and TSS (p = .022, .049, and
.034, respectively) (Table 3).
Regarding PedsQL-P mean scores, there was a sig-
nificant difference between groups in PFS, SoFS, and
TSS, suggesting parents of children with vitiligo tended
Table 1. Age distribution among groups.
Group
Age Statistical analysisa
Mean SD t p
Vitiligo 10.71 2.21 −0.942 .350
Control 11.20 2.12
aStudent’s t test.
Table 2. Gender distribution among groups.
Girls Boys Total
Statistical
analysisa
n % n % n % X2 p
Vitiligo 22 53.7 19 46.3 41 100 0.255 .337
Control 12 40.0 18 60.0 30 100
Total 34 47.9 37 52.1 71 100
aChi-square test.
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to evaluate their children rather differently than the
parents of the control group children, regarding
above-mentioned domains. Statistically significant
PedsQL-P mean scores were p = .044, .004, and .005,
respectively (Table 3).
No statistical significance was found between two
groups regarding CDI and STAI-C scores (Table 4).
Parents of children with vitiligo scored higher com-
pared to those of the control group, in scales rating
depressive symptoms (p = .013 via BDI), although no
difference was found regarding anxiety symptoms
(measured by BAI) (Table 4).
Of 41 children and adolescents diagnosed with viti-
ligo, 7 (17.1%) had a prior history of application to a
psychiatry unit for treatment, while 34 (82.9%) did not.
While 20 (48.8%) of 41 cases were able to identify a
stressful life event prior to onset of vitiligo, 21 (51.2%)
did not.
When variables affecting the severity of vitiligo were
evaluated via logistic regression analysis model, it was
seen that among variables identified as being statisti-
cally significant upon primary analyses, PedsQL-C
and PedsQL-P subscale scores, mean BDI scores sug-
gestive of parental depressive symptoms, or sociode-
mographic characteristics of participants did not
predict the severity of vitiligo.
Discussion
In this study (where children aged between 9 and 18
years and their parents were evaluated in a psychiatric
setting), we aimed to assess anxiety, depression, and
quality of life in children and adolescents diagnosed
with vitiligo, in comparison with their healthy counter-
parts, as well as their parents by using valid and reliable
instruments for measurement.
We have observed that children with vitiligo had a
significant difference in school, psychosocial, and
total scale domains of PedsQL, when compared to
those of the control group. Parents of children with
vitiligo had identified them rather differently than the
parents of the control group did, with respect to their
perceptions of their child’s physical health, social func-
tioning, and in total measures. Disruption in quality of
life is reported to be related to vitiligo severity and the
distribution of lesions [65]. In their study, Çakın-
Memik et al. [64] stress out the importance of sustain-
ing knowledge regarding the perceptions about health-
related quality of life of children with chronic disorders
to determine to what extent the condition has an effect
as variables such as individual differences among
people regarding physical and psychic health, indepen-
dence level, social interactions, family relationships,
social factors, belief systems, and future expectations
altogether shape the term quality of life [66]. Vitiligo
during childhood has negative impacts on quality of
life, through reported difficulties in self-assurance,
peer relationships, and problems in school functioning
[65]. Parsad et al. [2] have reported higher odds of
avoiding social activities and a decline in school attend-
ance in children diagnosed with vitiligo, compared to
the control group. Another study originating from
the Netherlands has reported the detrimental effect of
the disorder on social development continued through
adulthood, as well [7]. According to the results of
another recently made study, that is worthy of elabor-
ate interpretation, where the effects of skin disorders
emerging at childhood on life quality was assessed, it
was found that cases with vitiligo had lower self-
esteem, were much more socially stigmatized, had
much more experiences of shame, avoiding proximity,
anxiety, depression, adjustment disorder, fear, suicidal
ideation, and other psychiatric conditions [42].
According to the results of a research made online
with participants aged between 15 and 17 years, it
was found that vitiligo types with lesions located on
the face, arms, and legs caused much more stress,
and related to teasing and bullying [25]. PedsQL-C
scores in our study, differences present in ScFS,
PHSS, and TSS among children and adolescents diag-
nosed with vitiligo might indicate that our cases also
had some difficulties within these domains, possibly
reflecting a preference of staying away from school
due to their skin condition. Considering mean age of
Table 3. Comparison of groups by mean PedsQL-C and
PedsQL-P scores.
PedsQL-C scores
Vitiligo Control
Statistical
analysis*
Mean SD Mean SD t p
PFS 77.7 16.9 83.9 13.7 0.405 .110
EFS 70.6 21.2 74.0 17.1 −0.705 .483
SoFS 87.8 18.0 92.0 11.3 −1.110 .271
ScFS 73.0 17.9 81.8 12.9 −2.257 .022
PHSS 73.3 21.7 82.7 11.7 −2.004 .049
TSS 77.0 13.2 83.8 12.6 −2.159 .034
PedsQL-P scores
Vitiligo Control
Statistical
analysisa
Mean SD Mean SD t p
PFS 71.5 21.8 81.0 16.8 −2.056 .044
EFS 68.6 17.9 72.0 19.0 −0.759 .451
SoFS 76.7 19.8 90.0 15.6 −3.017 .004
ScFS 75.2 19.0 79.1 17.2 −0.886 .379
PHSS 73.3 21.7 82.2 11.7 −2.004 .097
TSS 72.3 13.3 82.0 14.8 −2.885 .005
Notes: PFS, physical functioning score; EFS, emotional functioning score;
SoFS, social functioning score; ScFS, school functioning score; PHSS, psy-
chosocial health summary score; and TSS, total scale score.
aStudent’s t test.
Table 4. Comparison of depression and anxiety measures
between vitiligo and control groups.
Mean score of scales Vitiligo (n:41) Control (n:30) t pa
CDI 6.8 ± 4.6 6.4 ± 5.5 0.321 .749
A-State 44.9 ± 6.1 46.5 ± 3.9 −1.235 .221
A-Trait 46.5 ± 5.1 44.6 ± 3.6 1.696 .079
BDI 14.6 ± 12.4 8.7 ± 6.7 2.342 .013
BAI 12.8 ± 14.1 9 ± 7.8 −1.326 .189
Notes: CDI, Children’s Depression Inventory; A-State, State Anxiety Inven-
tory for Children; A-Trait, Trait Anxiety Inventory for Children; BDI, Beck
Depression Inventory; and BAI, Beck Anxiety Inventory.
aStudent’s t test.
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our study group and how physical appearance plays
an important role in forming an identity and percep-
tion of one’s self during those years, having a visible
skin condition might negatively impact quality of
life and school functioning as a subdomain where
he/she is in a close and ongoing relationship with
her peers, not to mention the emergence of possible
psychiatric diagnoses arising secondary to the skin
condition, in turn, affecting overall life quality even
more adversely.
As parents of children and adolescents diagnosed
with vitiligo scored lower on PFS as well as SoFS and
TSS subdomains of PedsQL-P form, this might indicate
a similar interpretation to what has been discussed in
studies by Achenbach [67] and Eiser [68] that parents
might have a tendency to perceive their children’s qual-
ity of life worse than how their children self-evaluate on
physical domains. We might pose the same argument
as children with vitiligo did not report worse quality
on their own physical domain. An overall decrease in
quality of life secondary to vitiligo causing social retrac-
tion and isolation might cause parents to have a per-
ception of their children as if they are weaker on a
physical well-being level, as well. Concerns about social
domain were a common ground as reflected through
similar assessments of both children and parents, indi-
cating a decrease in quality of life scores from that
aspect. This might be caused by the negative impact
of the disorder on self-concept and identity related to
physical appearance, but might also indicate the pres-
ence of a psychiatric disorder present before vitiligo
emerged clinically.
In their study where three types of dermatoses were
compared, Manzoni et al. [69] have found that having a
diagnosis of any of the three declined health-related
quality of life, though suggesting that individuals with
atopic dermatitis and psoriasis had significantly lower
levels of life quality, compared to those diagnosed
with vitiligo. As part of the discussion, the authors
interpreted this difference by the possibility of individ-
uals with vitiligo, having no visible alteration in
appearance, or having less number of afflicted body
parts, compared to other two dermatoses [69]. Overall
impairment of children’s quality of life, and specifically
self-awareness and bullying and teasing of peers were
related to the severity of the disorder; not to mention
differences in where lesions would be distributed
were linked to different levels of impairment in the
sense of health-related quality of life. It has been stated
before that adolescents between ages 15 and 17 years
would be more likely to have more experience in self-
awareness, compared to those in pediatric age group,
which might have had an effect on the above-men-
tioned situation [25]. We have observed that severity
of the disorder did not have any effect on quality of
life in our sample. This finding might be related to
VASI mean scores of the patients being calculated as
3.3 ± 2.9 (1–16) and individuals with severe types of
the disorder being fewer in the whole group. While
depressive symptoms of parents who had children
with vitiligo were much more higher than that of con-
trol group parents, similar connection was not
observed for anxiety symptoms. With respect to chil-
dren’s level of anxiety and depression symptoms, no
difference was found between two groups. Chan et al.
[50] have reported a rate of 16.2% for depressive symp-
toms, while Sampogna et al. [6] have reported the rate
as 31.0%, and that the symptoms were related to quality
of life. It was concluded that life quality subscale scores
and level of parental depressive symptomatology did
not predict the severity of vitiligo.
Sukan and Maner [70] reported that assessing psy-
chosocial status of the caregivers and family function-
ing would be important in the course of skin
disorders, planning appropriate treatment, and for
future studies that would be conducted within the
field of psychodermatology. Low self-esteem and self-
reports of social isolation due to feelings of shame
have been reported by many patients with vitiligo
[41]. Moral et al. have reported a rate of depression
as 34%, according to BDI and anxiety as 60%, accord-
ing to BAI, in their sample [71]. In his 2013 study,
Manzoni has also reported higher levels of anxiety
and depression, compared to that observed in general
population, in parents of children from all interior-der-
matosis groups (atopic dermatitis, psoriasis, and viti-
ligo – 26% depression and 42% anxiety) [72]. In our
study, we have found no difference regarding
depression and anxiety scale scores between children
and adolescents in vitiligo group and healthy control
group, while higher mean depression score was
measured in parents of children with vitiligo compared
to those from healthy control group. In a study by Prcic
et al. [73] where 33 adolescents with vitiligo and 60
healthy controls were compared, no significant differ-
ence for depression and anxiety scores was observed
between groups. Many observational research exist
that favour the idea that an epidemiological link
would be present between vitiligo and psychiatric dis-
orders such as depression [74,75], as well as many
other studies failing to find any connection [76,77].
In many studies, depressive symptoms have been
assessed with the help of psychometric instruments,
and a few studies had been carried out with a psychia-
tric assessment based on a semi-structured interview,
through a review of diagnostic criteria from Diagnostic
and Statistical Manual for Mental Disorders (DSM).
A great number of different rating scales to assess
depression exist in different countries. We might
speculate that one possible reason for not establishing
a difference in depression and anxiety mean scores of
children with vitiligo and healthy controls could arise
from the probable protective effect of prior positive his-
tory for psychiatric help in 17.1% of patients.
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There was no significant difference among two
groups regarding anxiety levels of parents. However,
higher mean depression scores obtained in parents of
children with vitiligo might indicate that the presence
of this chronic disorder could affect both parents’
and their children’s quality of life negatively through
causing an adverse impact on their social, emotional,
and academic functions, in turn, creating greater vul-
nerability for depression, on the part of parents. In a
study by Bilgiç et al. [75], it was established that sever-
ity of vitiligo was related to psychiatric well-being of
the mothers. Low levels of anxiety detected in children
might be related to low levels of parental anxiety. As a
condition that would possibly disrupt the fantasy of the
idealized child, the child might be affected too, in case
of insufficient adaptive mechanisms and the prob-
ability of parents reflecting their psychological distress
on their children [35,38,78]. Our findings of parental
anxiety levels not being higher than those in the control
group might have created a positive effect such as mod-
erate levels of anxiety in children and medium levels of
vitiligo severity. When type of stress as a triggering fac-
tor before the onset of vitiligo was questioned, it was
reported that 65% of patients had described a stressful
event prior to the condition and 45.6% of this group
described having family problems [3]. A well-defined
stressor prior to the onset of the condition was found
in 48.8% of the cases in our study, while this might
be due to the limited time span of our study and the
relatively small number of cases included. We might
argue that in a wider time range and with larger sample
size, one might reach higher rates similar to what has
been reported so far in the literature. The extent of
the effect vitiligo has on quality of life might alter
with age groups. In their study, Bilgic et al. [27] have
stated that severity of vitiligo correlated with severity
of depression in prepubertal children, however con-
nected to decreased levels of life quality in adolescents.
The need to get over lots of stressful process of passage,
starting from very early ages might have a negative
impact on quality of life [8]. When our case group
was redefined and grouped as prepubertal and adoles-
cent groups, no significant difference between groups
was observed, with respect to scores of scales measur-
ing the child’s and his parent’s level of depression,
anxiety, and quality of life. Relatively fewer number
of adolescents in vitiligo group was thought to have
contributed to this consequence. In cases that are
older, the more level of exposure to the illness, higher
would be the possibility of encountering much more
negative consequences linked to levels of life quality.
In contrast to significant results obtained in adults, fail-
ure to collect similar information might be related to
the relatively shorter period of exposure to the dis-
order, compared to others that are older.
Single variance analyses have suggested a significant
difference existed between quality of life (child and
parent) and parental depression scale. However,
when mutlivariance analyses were performed, there
was no significant relationship between severity of
the disorder and sociodemographic characteristics of
participants and again, there was no significant
relationship between quality of life and levels of par-
ental depression. Logistic regression analyses might
be affected by lots of factors. Parents and children hav-
ing different perceptions over quality of life and small
sample size might have contributed to failing to obtain
a meaningful result when logistic regression analysis
was applied. Our study was a single-centred study
with relatively small sample size; therefore, findings
of the study could not be generalized to all Turkish
children, that might as well be considered among the
limitations of the study. Heterogeneous background
of parents, different periods of time elapsed upon
being diagnosed, for each case and possibility of recall
and/or reporting bias regarding stressors and psychia-
tric history of the children might be other limitations of
the study. The fact that no structured clinical interview
was carried out with cases and relying on symptoms
identified through self-evaluation of patients and
parents might be considered as another limitation.
Another one might be that level of life quality was
measured only once. Since vitiligo is a chronic skin
condition, changes occurring within quality of life
through the process might be important to assess and
address. Failure to interrogate the patients and their
parents for the presence of other autoimmune con-
ditions and evaluating quality of life by the location
of lesions were thought as other limitations of the
study. As this study was of cross-sectional nature,
further need of future longitudinal studies with longer
time span and bigger sample size are warranted, in
order to generalize the study findings to the whole
population.
Despite its many potential limitations, we believe
the strength and significance of this study arose since
it is an important contribution to limited number of
relevant studies in the field, through aiming to explore
levels of life quality, symptoms of depression, and
anxiety in childhood – onset vitiligo. With its preva-
lence reported to be 1% of general population, where
majority of diagnosed individuals were reported to be
under 20 years old [6,7], research conducted with the
participation of children and adolescents would be of
great importance.
As for the treatment process, focusing beyond clini-
cal severity, and elucidating all possible factors –
including psychological effects – that might help
throughout the process would be really important.
Increasing awareness and recognition of the impor-
tance of life quality in vitiligo and the contribution it
has provided to determine such factors that affect
health-related quality of life might be counted as the
strengths of this study. Even though studies aiming
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to cover the possible psychiatric effects of vitiligo
throughout childhood and adolescence exist in other
countries, still, limited number of research is present
in our country. Being a prospective study that had
employed valid and reliable instruments (PedsQL,
BDI, BAI, CDI, STAI, etc.) might be regarded as
another strength of our study.
Conclusion
We believe that determination of life quality of a cer-
tain individual through employing standardized pro-
cedures is important to evaluate conditions of
patients at pre- and posttreatment, as well as being
able to assess efficiency and consequences of treatment.
For all these reasons, carrying out further studies
that focus on improving overall quality of life, specifi-
cally for children and adolescents with chronic health
issues is important. Moreover, clinicians need to be
able to evaluate psychiatric symptomatology such as
depression and anxiety in cases of vitiligo, and refer
them for appropriate treatment. Results of our study
support prior findings that suggest lower levels of life
quality in vitiligo patients.
Acknowledgements
All authors have contributed significantly to the study.
Disclosure statement
No potential conflict of interest was reported by the authors.
References
[1] Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a
review of the published work. J Dermatol. 2011;38
(5):419–431.
[2] Parsad D, Dogra S, Kanwar AJ. Quality of life in
patients with vitiligo. Health Qual Life Outcomes.
2003;23;1:58.
[3] Görpelioğlu C. Vitiligoda psikolojik faktörler. Turkiye
Klinikleri J Dermatol-Special Topics. 2009;2(4):66–70.
[4] Koblenzer CS. Psychosomatic concept in dermatology.
Arch Dermatol. 1983;119:501–512.
[5] Krüger C, Schallreuter KU. A review of the worldwide
preva-lence of vitiligo in children/adolescents and
adults. Int J Dermatol. 2012; 51:1206.
[6] Sampogna F, Raskovic D, Guerra L, et al. Identification
of categories at risk for high quality of life impairment
in patients with vitiligo. Br J Dermatol. 2008;159:351–
359.
[7] Linthorst Homan MW, de Kor te J, Grootenhuis MA,
et al. Impact of childhood vitiligo on adult life. Br J
Dermatol. 2008;159:915–920.
[8] Arıcan Ö, Koç K, Kutluk R, et al. Vitiligolu hastalarda
serum vitamin B12 ve folik asit düzeyleri. T Klin
Dermatoloji. 2003;13:4–10.
[9] Van Moffaert M. Psychodermatology: an overview.
Psychoder Psychosom. 1992;58:125–136.
[10] Koo JYM, Pham CT. Psychodermatology: practical
guidelines on pharmacotherapy. Arch Dermatol.
1992;126:381–388.
[11] Van Moffaert M. Psychodermatology: an overview.
Psychother Psychosom. 1992;58:125–136.
[12] Ramrath K, Stolz W. Disorders of melanin pigmenta-
tion. In: Burgdorf WHC, Plewig G, Wolf HH,
Lanthaler M, editors. Braun-Falco’s dermatology. 3rd
ed. Heidelberg: Springer Medizin Verlag; 2009. p.
957–982.
[13] Jafferany M. Psychodermatology: a guide to under-
standing common psychocutaneous disorders. Prim
Care Companion J Clin Psychiatry. 2007;203–213.
[14] Ludwig MWB, Muller MC, Oliveira MS, et al.
Qualidade de vida e localização das lesões em pacientes
dermatológicos. An Bras Dermatol. 2009;84:143–150.
[15] Kossakowska MM, Cieciska C, Jaszewska J, et al.
Control of negative emotions and its implication for ill-
ness perception among psoriasis and vitiligo patients. J
Eur Acad Der matol Venereol. 2010;24:429–433.
[16] Krüger C, Schallreuter KU. CLCI in vitiligo. In: Linder
MD, Kimball AB, editors. Dermatological diseases and
cumulative life course impairment. Basel: Karger, 2013.
p. 102–117.
[17] Ramien ML, Ondrejchak S, Gendron R, et al. Quality of
life in pediatric patients before and after cosmetic
camouflage of visible skin conditions. J Am Acad
Dermatol. 2014;71:935–940.
[18] Eleftheriadou V, Thomas KS, Whitton ME, et al.
Which outcomes should we measure in vitiligo?
Results of a systematic review and a survey among
patients and clinicians on outcomes in Vitiligo trials.
Br J Dermatol. 2012;167:804–814.
[19] Lilly E, Lu PD, Borovicka JH, et al. Development and
validation of a vitiligo-specific quality- of-life instru-
ment (VitiQoL). J Am Acad Dermatol. 2013;69:e11–
e18.
[20] Choi S, Kim DY, Whang SH, et al. Quality of life and
psychological adaptation of Korean adolescents with
vitiligo. J Eur Acad Dermatol Venereol. 2010;24:524–
529.
[21] Al-Shobaili HA. Treatment of vitiligo patients by exci-
mer laser improves patients’ quality of life. J Cutan
Med Surg. 2014;18:1–7.
[22] Sehgal V, Serivastava G. Vitiligo: Compendium of clin-
ico epidemiological features. (Review Article) (Disease/
Disorder overview). Indian J Dermatol Venereol
Leprol. 2007;73:123–129.
[23] Porter J, Beuf AH. Racial variation in reaction to phys-
ical stigma: A study of degree of disturbance by vitiligo
among black and white patients. J Health Soc Behav.
1991;32:192–204.
[24] Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A,
et al. Quality of life with vitiligo: comparison of male
and female Muslim patients in Iran. Gender Med.
2006;3:124–130.
[25] Silverberg JI, Silverberg NB. Quality of life impairment
in children and adolescents with vitiligo. Pediatr
Dermatol. 2014;31(3):309–318.
[26] Dertlioglu SB, Cicek D, Balci DD, et al. Dermatology
life quality index scores in children with vitiligo: com-
parison with atopic dermatitis and healthy control sub-
jects. Int J Dermatol. 2013;52:96–101.
[27] Bilgic O¸ Bilgic A, Akis HK, et al. Depression, anxiety
and health-related quality of life in children and ado-
lescents with Vitiligo. Clin Exp Dermatol. 2011;36
(4):360–365.
8 Ö. ÖNEN ET AL.
[28] Carroll CL, Balkrishnan R, Feldman SR, et al. The bur-
den of atopic dermatitis: impact on the patient, family,
and society. Pediatr Dermatol. 2005;22:192–199.
[29] Bick E. The experience of skin in early object relations.
Int J Psychoanal. 1968;49:484–486.
[30] Hayes J, Koo J. Psoriasis: depression, anxiety, smoking,
and drinking habits. Dermatol Ther. 2010;23:174–180.
[31] Cvetkovski RS, Zachariae R, Jensen H, et al. Quality of
life and depression in a population of occupational
hand eczema patients. Contact Dermatitis.
2006;54:106–111.
[32] Hong J, Koo B, Koo J. The psychosocial and occu-
pational impact of chronic skin disease. Dermatol
Ther. 2008;21:54–59.
[33] Loney T, Standage M, Lewis S. Not just ’skin deep’:
psychosocial effects of dermatological-related social
anxiety in a sample of acne patients. J Health
Psychol. 2008;13:47–54.
[34] Fried RG, Gupta MA, Gupta AK. Depression and skin
disease. Dermatol Clin. 2005; 23:657–664.
[35] Picardi A, Pasquini P, Abeni D, et al. Psychosomatic
assessment of skin diseases in clinical practice.
Psychother Psychosom. 2005;74:315–322.
[36] Ricci G, Bendandi B, Aiazzi R, et al. Three years of
Italian experience of an educational program for
parents of young children affected by atopic dermatitis:
improving knowledge produces lower anxiety levels in
parents of children with atopic dermatitis. Pediatr
Dermatol. 2009;26:1–5.
[37] Goh C, Lane AT, Bruckner AL. Support groups for
children and their families in pediatric dermatology.
Pediatr Dermatol. 2007;24:302–305.
[38] Schwartz R, Sepúlveda JE, Quintana T. Possible role of
psychological and environmental factors in the genesis
of chilhood vitiligo. Rev Med Chil. 2009;137:53–62.
[39] Fortune DG, Richards HL, Kirby B, et al. A cognitive-
behavioral symptom management programme as an
adjunct un psoriasis therapy. Br J Dermatol.
2002;146:458–465.
[40] Kotrulja L, Tadinac M, Joki-Begi NA, et al. A multi-
variate analysis of clinical severity, psychological dis-
tress and psychopathological traits in psoriatic
patients. Acta Derm Venereol. 2010;90:251–256.
[41] Chua TL, Goh BK, Aw CW, et al. Investigating factors
associated with depression of Vitiligo patients in
Singapore. J Clin Nurs. 2012;21:1614–1621.
[42] Brown MM, Chamlin SL, Smidt AC. Quality of life in
pediatric dermatology. Dermatol Clin. 2013;31(2):211–
221.
[43] Sangma LN, Nath J, Bhagabati D. Quality of life and
psychologi-cal morbidity in vitiligo patients: A study
in a teaching hospital from north-East India. Indian J
Dermatol. 2015;60:142–146.
[44] Namazi MR. Prescribing cyclic antidepressants for viti-
ligo patients: which agents are superior, which are not?
Psychother Psychosom. 2003;72:361–362.
[45] Firooz A, Bouzari N, Fallah N, et al. What patients with
Vitiligo believe about their condition. Int J Dermatol
2004;43:811–814.
[46] Morrone A, PicardoM, de Luca C, et al. Catecholamines
and vitiligo. Pigment Cell Res. 1992;5:65–69.
[47] Stokes PE, Sikes CR. The hypothalamic-pituitary-adre-
nocortical axis in major depression. Neurol Clin.
1988;6:1–19.
[48] Sharma N, Koranne RV, Singh RK. Psychiatric mor-
bidity in psoriasis and vitiligo: a comparative study. J
Dermatol. 2001; 8:419–423.
[49] Lai YC, Yew YW, Kennedy C, et al. Vitiligo and
depression: a systematic review and meta-analysis of
observational studies. Br J Dermatol. 2017;177
(3):708–718.
[50] Chan MF1, Chua TL, Goh BK, et al. Investigating fac-
tors associated with depression of vitiligo patients in
Singapore. J Clin Nurs. 2012;21(11–12):1614–1621.
[51] Thompson AR, Kent G, Smith JA. Living with Vitiligo:
dealing with difference. Br J Health Psychol.
2002;7:213–225.
[52] Hamzavi I, Jain H, McLean D, et al. Parametric mod-
elling of narrowband UV-B phototherapy for vitiligo,
using a novel quantitative tool: the Vitiligo Area
Scoring Index. Arch Dermatol. 2004;140(6):677–683.
[53] Kovacs M. The Children’s Depression Inventory
(CDI). Psychopharmacol Bull. 1985;21:995–998.
[54] Öy B. Çocuklar için depresyon ölçeği geçerlik
vegüvenirlik çalışması [Validity and reliability study
of children’s depression inventory]. Türk Psikiyatri
Dergisi. 1991;2:132–137.
[55] Beck AT, Ward CH, Mendelson M, et al. An inventory
for measuring depression. Arch Gen Psychiatry.
1961;4:561–571.
[56] Hisli N. Beck Depresyon Envanterinin geçerliği üzerine
bir çalışma [A study on validity of beck depression
inventory]. Psikoloji Dergisi 1988;6(22):118–122.
[57] Spielberger CD. Manual for the state-trait anxiety
inventory for children. Palo Alto: Consulting
Psychologist Press; 1973.
[58] Özusta HŞ. Çocuklar için Durumluk-Sürekli Kaygı
Envanteri Uyarlama, Geçerlik ve Güvenirlik
Çalışması [Adaptation, validity and reliability study
of statetrait anxiety inventory for children]. Türk
Psikoloji Dergisi; 1995
[59] Beck AT, Epstein N, Brown G, et al. An inventory for
measuring clinical anxiety: psychometric properties. J
Consult Clin Psychol. 1988;56(6):893–897.
[60] Ulusoy. Beck Anksiyete Envanteri: Geçerlik ve güvenirlik
çalışması. [Beck Anxiety Inventory: Validity and
Reliability Study]. İstanbul: Yayınlanmamış uzmanlık
tezi, 1993;Bakırköy Ruh ve Sinir Hastalıkları Hastanesi.
[61] Varni JW, Said M, Rode CA. The PedsQL: measure-
ment model for the pediatric quality of life inventory.
Med Care. 1999;37:126–139.
[62] Varni JW, Said M, Kurtin PS. PedsQL 4.0: reliability
and validity of the pediatric quality of life inventory
version 4.0 generic core scales in healthy and patient
populations. Med Care. 2001;39:800–812.
[63] Memik NÇ, Ağaoğlu B, Coşkun A, et al. Çocuklar için
yaşam kalitesi ölçeğinin 8–12 yaş çocuk formunun
geçerlik ve güvenirliği [Turkish validity and reliability
study of pediatric quality of life scale–child form for
8–12 years]. Çocuk ve Gençlik Ruh Sağlığı Dergisi.
2008;15(2).
[64] Memik NÇ, Ağaoğlu B, Coşkun A, et al. Çocuklar İçin
Yaşam Kalitesi Ölçeğinin 13–18 Yaş Ergen Formunun
Geçerlik Ve Güvenilirliği [Turkish validity and
reliability study of pediatric quality of life scale–adoles-
cent form for 13–18 years]. Türk Psikiyatri Dergisi.
2007;18(4):353–363.
[65] Silverberg JI, Silverberg NB. Association between viti-
ligo extent and distribution and quality-of-life impair-
ment. JAMA Dermatol. 2013;149(2):159–164.
[66] Memik NÇ, Ağaoğlu B, Coşkun A. Tip 1 diyabetes mel-
litusu olan çocuk ve ergenlerin yaşam kalitesi algılarının
değerlendirilmesi [Assessment of perceptions of quality
of life in children and adolescents diagnosed with Type-I
PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY 9
Diabetes Mellitus]. Çocuk ve Gençlik Ruh Sağlığı
Dergisi. 2007;14:133–138.
[67] Achenbach TM, McConaughy SH, Howell CT. Child/
adolescent behavioural and emotional problems:
implications of crossinformant correlations for situa-
tional specificity. Psychol Bull. 1987;101(2):213–232.
[68] Eiser C, Morse R. Can parents rate their child’s health-
related quality of life? Results of a systematic review.
Qual Life Res 2001;10:347–357.
[69] Manzoni APDS, Pereira RL, Townsend RZ, et al.
Assessment of the quality of life of pediatric patients
with the major chronic childhood skin diseases. An
Bras Dermatol. 2012;87(3):361–368.
[70] Sukan M, Maner F. Stres Yaratan Yaşam Olaylarının
Vitiligo ve Kronik Ürtiker Hastalarına Etkisi [Effects
of stressful life events on patients with Vitiligo and
Urticaria]. Klinik Psikiyatri. 2006;9:17–26.
[71] Morales-Sánchez MA, Vargas-Salinas M, Peralta-
Pedrero ML, et al. Impact of Vitiligo on quality of
life. Actas Dermosifiliogr. 2017;108(7):637–642.
[72] Manzoni APDS, Weber MB, Nagatomi ARS, et al.
Assessing depression and anxiety in the caregivers of
pediatric patients with chronic skin disorders. An
Bras Dermatol. 2013;88(6):894–899.
[73] Prcic S, Durovic D, Duran V, et al. Some psychological
characteristics of children and adolescents with Vitiligo
- Our results. Medicinski Pregled. 2006;59:265–269.
[74] Mattoo SK, Handa S, Kaur I, et al. Psychiatric morbid-
ity in Vitiligo: prevalence and correlates in India. J Eur
Acad Dermatol Venereol. 2002;16:573–578.
[75] Bilgiç Ö, AkışHK, Eskioğlu F. The impact of childhood
Vitiligo and Psoriasis on parents’ mental health and
family functioning. Anatolian J Clin Invest. 2011;5
(4):160–164.
[76] Kent G, Al’Abadie M. Psychologic effects of vitiligo: a
critical incident analysis. J Am Acad Dermatol.
1996;35:895–898.
[77] Picardi A, Abeni D, Melchi CF et al. Psychiatric mor-
bidity in dermatological outpatients: an issue to be
recognized. Br J Dermatol. 2000;143:983–991.
[78] Kruger C, Schallreuter KU. Stigmatisation, avoidance
behaviour and difficulties in coping are common
among adult patients with vitiligo. Acta Derm
Venereol. 2015;95:553–558.
10 Ö. ÖNEN ET AL.
